Mgc Pharmaceuticals Stock Net Asset
| MGCLFDelisted Stock | USD 0.21 0.00 0.00% |
MGC Pharmaceuticals fundamentals help investors to digest information that contributes to MGC Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of MGC OTC Stock. The fundamental analysis module provides a way to measure MGC Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MGC Pharmaceuticals otc stock.
MGC |
MGC Pharmaceuticals OTC Stock Net Asset Analysis
MGC Pharmaceuticals' Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Current MGC Pharmaceuticals Net Asset | 22.6 M |
Most of MGC Pharmaceuticals' fundamental indicators, such as Net Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MGC Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Net Asset is the value used in calculating NAV of a fund. NAV (or Net Asset Value) is computed once a day based on the formula that uses closing prices of all positions in the fund's portfolio.
CompetitionBased on the recorded statements, MGC Pharmaceuticals has a Net Asset of 22.6 M. This is much higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The net asset for all United States stocks is notably lower than that of the firm.
MGC Net Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MGC Pharmaceuticals' direct or indirect competition against its Net Asset to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of MGC Pharmaceuticals could also be used in its relative valuation, which is a method of valuing MGC Pharmaceuticals by comparing valuation metrics of similar companies.MGC Pharmaceuticals is currently under evaluation in net asset category among its peers.
MGC Fundamentals
| Return On Equity | -2.19 | |||
| Return On Asset | -0.45 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 24.97 M | |||
| Shares Outstanding | 2.87 B | |||
| Shares Owned By Insiders | 9.10 % | |||
| Shares Owned By Institutions | 6.12 % | |||
| Price To Book | 5.69 X | |||
| Price To Sales | 5.81 X | |||
| Revenue | 4.65 M | |||
| Gross Profit | 562.87 K | |||
| EBITDA | (16.44 M) | |||
| Net Income | (20.35 M) | |||
| Cash And Equivalents | 1.89 M | |||
| Total Debt | 4.35 M | |||
| Debt To Equity | 0.84 % | |||
| Current Ratio | 0.84 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (12.16 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 16 | |||
| Beta | 1.23 | |||
| Market Capitalization | 17.2 M | |||
| Total Asset | 22.6 M | |||
| Z Score | 1.8 | |||
| Net Asset | 22.6 M |
About MGC Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze MGC Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MGC Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MGC Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Other Consideration for investing in MGC OTC Stock
If you are still planning to invest in MGC Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MGC Pharmaceuticals' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |